FIELD: medicine.
SUBSTANCE: invention relates to use of compounds, the structural formula of which is given below, or pharmaceutically acceptable salts thereof as an active ingredient of a therapeutic or prophylactic drug for diabetic nephropathy, particularly nephropathy caused by type II diabetes.
EFFECT: said compounds have higher activity with respect to reducing albumin level and higher therapeutic effectiveness in treating and preventing diabetic nephropathy.
1 cl, 8 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZOLE DERIVATIVES OF BENZENE | 2014 |
|
RU2641891C2 |
| APPLICATION OF VASOPEPTIDASE INHIBITORS IN PATIENTS WITH NEPHROPATHY | 2003 |
|
RU2336080C2 |
| USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN | 2012 |
|
RU2608943C2 |
| APPLICATION OF THIAZOLIDINEDIONES FOR PREVENTION OR ONSET POSTPONEMENT OF INSULIN-INDEPENDENT DIABETES MELLITUS (NIDDM) | 1994 |
|
RU2195282C2 |
| ENDOPARASITE CONTROL AGENT | 2012 |
|
RU2596788C2 |
| PANCREATIC DIABETES DRUG | 2004 |
|
RU2358738C2 |
| MEDICINAL COMPOSITIONS | 1997 |
|
RU2197226C2 |
| 3,4-DIHYDROBENZOXAZINE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | 2006 |
|
RU2427579C2 |
| DEHALOGENATED COMPOUNDS, ANTIBACTERIAL AGENT AND THERAPEUTIC AGENT BASED ON THEREOF, METHOD FOR PREPARING ANTIBACTERIAL OR MEDICINAL AGENT, USING DEHALOGENATED COMPOUNDS FOR PREPARING ANTIBACTERIAL OR MEDICINAL AGENT | 2001 |
|
RU2298006C2 |
| PROTEINURIA TREATMENT | 2019 |
|
RU2805150C2 |
